发现和描述具有激动性活动的小分子TGR5配体
M Giovanna E Papadopoulos1, Alexander F Perhal2, Brian Medel-Lacruz3
1Department of Pharmaceutical Chemistry, University of Marburg, Marburg, Germany.
European journal of medicinal chemistry
|July 12, 2024
概括
研究人员确定了Takeda G蛋白结合受体5 (TGR5) 的小分子激活剂和正调节剂,这是代谢和炎症疾病的潜在目标.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 塔凯达的G蛋白结合受体5 (TGR5) 被胆酸激活.
- 在炎症和代谢疾病中,TGR5是一个有前途的治疗点.
研究的目的:
- 通过基于结构的药物设计来识别针对TGR5的小分子配体.
- 为了探索TGR5调节的orthosteric和allosteric结合位.
主要方法:
- 利用实验和模拟的TGR5结构用于基于结构的连接体发现.
- 采用了分子动力学模拟和体外表征.
主要成果:
- 确定了TGR5.5的新型激动剂和正调节剂 (PAMs).
- 在体外鉴定了鉴定到的配体的特征,尽管预测的结合部位和疗效存在差异.
结论:
- 成功开发了TGR5.5的小分子激活配体.
- 这项工作为进一步的TGR5研究和治疗开发提供了有价值的工具.
相关概念视频
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K
Drug-Receptor Interactions
5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
GPCR Desensitization
5.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.9K
GPCRs Regulate Adenylyl Cylase Activity
5.4K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.4K


